ATNM Actinium Pharmaceuticals Inc. (Delaware)

0.24
+0.01  (+5%)
Previous Close 0.23
Open 0.22
Price To Book 3.97
Market Cap 39,248,288
Shares 164,701,167
Volume 3,243,823
Short Ratio 0.85
Av. Daily Volume 2,645,921
Stock charts supplied by TradingView

NewsSee all news

  1. Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients

    NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") announced today that it is expanding its CD33 program studying Actimab-A into a combination trial with the

  2. Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)

    NEW YORK, Feb. 21, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") announced today findings from the SIERRA trial that were presented at the 2020 Transplantation & Cellular

  3. Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary Results Selected for Oral Presentation

    NEW YORK, Feb. 13, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") announced today that presentations from its targeted conditioning portfolio have been accepted for presentation at

  4. Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

    NEW YORK, Feb. 5, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") today announced that Sandesh Seth, Actinium's Chairman & CEO, will be presenting at the 22nd Annual BIO CEO

  5. Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma

    NEW YORK, Jan. 13, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium"), announced today that it has entered into an agreement with the University of California, Davis (UC Davis) to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 trial planned, to be followed by pivotal trial.
Actimab-MDS
Myelodysplastic syndrome (MDS)
Phase 2 data presented at TAT April 2, 2019.
Actimab-A
Acute Myeloid Leukemia (AML)
Phase 3 data presented at ASH December 7, 2019.
Iomab-B
Acute myeloid leukemia (AML)
Phase 1 ongoing.
Actimab-M
Refractory multiple myeloma
Phase 1 data at ASH December 8, 2019. 86% ORR.
Actimab-A in combination with CLAG-M
Relapsed or refractory acute myeloid leukemia (AML)
Phase 1/2 trial initiation announced February 5, 2019.
Actimab-A and Venetoclax
Relapsed or refractory acute myeloid leukemia (AML)
Phase 1 initiation announced February 26, 2020.
Actimab-A in combination with chemotherapy regimen 7+3
Acute Myeloid Leukemia (AML)

Latest News

  1. Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients

    NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") announced today that it is expanding its CD33 program studying Actimab-A into a combination trial with the

  2. Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)

    NEW YORK, Feb. 21, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") announced today findings from the SIERRA trial that were presented at the 2020 Transplantation & Cellular

  3. Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary Results Selected for Oral Presentation

    NEW YORK, Feb. 13, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") announced today that presentations from its targeted conditioning portfolio have been accepted for presentation at

  4. Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

    NEW YORK, Feb. 5, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") today announced that Sandesh Seth, Actinium's Chairman & CEO, will be presenting at the 22nd Annual BIO CEO

  5. Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma

    NEW YORK, Jan. 13, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium"), announced today that it has entered into an agreement with the University of California, Davis (UC Davis) to

  6. Actinium Pharmaceuticals, Inc. to Present at 2020 Biotech Showcase™

    NEW YORK, Jan. 7, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") announced today that Sandesh Seth, Actinium's Chairman and CEO, will present at the 2020 Biotech Showcase™ being

  7. Actinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting

    NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") today highlighted new data from a Phase 1 trial studying Actimab-A in combination with the salvage chemotherapy

  8. Actinium Pharmaceuticals Announces Phase 3 SIERRA Trial Dosimetry Results Support Low Dose Iomab-B for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

    NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") presented new findings from its pivotal Phase 3 SIERRA trial for Iomab-B (Iodine-131 apamistamab) at the 2019

  9. Actinium Pharmaceuticals to Present at the 25th Annual BIO-Europe® 2019 International Partnering Conference

    NEW YORK, Nov. 7, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") announced today that it will attend the 25th Annual BIO-Europe® International Partnering Conference being held

  10. Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019

    NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") today announced that interim results from a Phase 1 trial studying Actimab-A in combination with CLAG-M have been

  11. Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019

    NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") today announced that new findings from its pivotal Phase 3 SIERRA trial for Iomab-B (Iodine-131 apamistamab) that

  12. Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment

    NEW YORK, Oct. 28, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") today announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B, including

  13. Actinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa

    NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") today announced that it will be attending the 2019 Cell & Gene Meeting on the Mesa being held October 2nd –

  14. Actinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred Abstracts

    NEW YORK, Sept. 23, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") today announced that a poster highlighting Iomab-B, its pivotal Phase 3 targeted conditioning candidate, was

  15. Actinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment

    NEW YORK, Sept. 16, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") today announced that it will present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering &

  16. Actinium Pharmaceuticals to Present at the Rodman & Renshaw 21st Annual Global Investment Conference

    NEW YORK, Sept. 5, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium"), today announced that it will present at the Rodman & Renshaw 21st Annual Global Investment Conference. The